CA 72.4 - Gastric Cancer Marker

CA 72.4 (CA 72‑4) is a blood tumor marker that detects a high‑molecular‑weight glycoprotein (TAG‑72) often elevated in gastric cancer. It’s used to monitor disease burden, treatment response, and detect recurrence, but it isn’t diagnostic alone—sensitivity and specificity are limited and levels can rise in other cancers or benign conditions. Results are interpreted with imaging, endoscopy, and clinical findings.

Normal CA 72‑4 (CA 72.4) is generally below about 6.9 U/mL, though some laboratories use cutoffs near 7–8 U/mL. Reference ranges vary by assay and lab; mildly raised values are not diagnostic on their own. Results should be interpreted with clinical context, imaging, and other tests, and elevated levels warrant follow-up or specialist review.

The primary "CA" tumor marker associated with gastric (stomach) cancer is CA 72-4 (CA72‑4). Other markers, such as CA 19‑9 and carcinoembryonic antigen (CEA), may also be elevated and are used alongside imaging and endoscopy for staging and monitoring. No single marker is diagnostic; serial levels help assess treatment response and detect recurrence rather than establish the initial diagnosis.

No—CA 72‑4 (a tumor‑marker blood test) generally does not require fasting. Most labs accept a non‑fasting sample, though some prefer a morning draw. Follow any specific lab instructions; avoid heavy exercise, recent alcohol or smoking before the test, and inform your clinician about medications or recent procedures that could affect results.

A doctor orders a CA72‑4 blood test to help evaluate and monitor certain cancers—especially gastric (stomach) and some ovarian, colorectal, or pancreatic tumors. It aids in assessing treatment response, tracking for recurrence, and providing prognostic information when used alongside imaging and other tumor markers. It’s not a standalone screening test because levels can be elevated in noncancerous conditions and sensitivity is limited.

Gastric cancer can be curable when detected very early: endoscopic removal or surgery (partial/total gastrectomy), often with chemotherapy and sometimes radiotherapy, may achieve cure. Locally advanced or metastatic disease is usually not curable; treatment then aims to prolong life and relieve symptoms. Prognosis depends on stage, tumor type and overall health, so early detection improves chances.